News & Updates

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022

In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
05 Jul 2022 byTristan Manalac

In men with metastatic prostate cancer, prior radical prostatectomy (RP) appears to reduce the risk of developing a castrate-resistant state, as compared with radiation therapy (RT), according to a recent study. Previous RP also seems to improve overall survival (OS).

Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
05 Jul 2022
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
05 Jul 2022 byChristina Lau

Using circulating tumour DNA (ctDNA) analysis to guide adjuvant treatment of stage II colorectal cancer (CRC) reduces adjuvant chemotherapy use without compromising recurrence-free survival (RFS) compared with standard management guided by clinicopathological criteria, results of a phase II randomized controlled trial have shown.

Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
05 Jul 2022